Oncotarget: определение коамплификаций онкогенов HER при раке груди

Oncotarget недавно опубликовал статью « Совместная работа для семьи: определение коамплификаций онкогенов HER при раке груди », в которой сообщается, что, несмотря на специфическое лечение, к сожалению, у 20% первичных и 70% метастатических опухолей HER2 развивается резистентность. Кроме того, авторы разработали протокол, основанный на комбинации MLPA с ddPCR для определения доли коамплифицированных HER в опухоли. На 111 IDC результаты HER2 MLPA были подтверждены FISH, CISH и IHC. Процент клеток с коамплифицированным HER2 варьировал среди опухолей. Независимые результаты in-silico показывают, что исход пациентов с HER2 обусловлен статусом HER3 и HER4. В Oncotarget результаты автора стимулировать дальнейшие исследования для изучения взаимосвязи с ответом пациента на одного или комбинированное лечение.

Комментарии

Отправить комментарий

Популярные сообщения из этого блога

Trending with Impact: Basal Cell Bladder Cancer and MEK Inhibitors

For patients with basal cell bladder cancer, researchers in this study identify MEK inhibitors as a viable therapeutic option. 3d Illustration - Bladder cancer cells 3d Illustration – Bladder cancer cell The Trending with Impact series highlights publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels. Look for future science news and articles about the latest trending publications here and at Oncotarget.com. — oncotarget submission “Basal bladder cancer is frequently clinically aggressive and has the worst overall prognosis [3], and thus, additional therapeutic options for these tumors would be highly clinically relevant.” In this paper published by Oncotarget, researchers from the University of Michigan conducted a study emphasizing the importance of 3D culture screenings versus 2D, and the use of MEK inhibitors to target basal cell bladder cancer. This paper concludes that basal cell blad
Далее...

hospitals in us

Изображение
When people refer to contemporary medicine, precision plays one of the most significant roles and human lives are directly dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the top standards. The problem nowadays is that any results of researches can be shared online and used as a reference without being adequately verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That allows both readers and authors to validate publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with corresponding s
Далее...

MRI and ADC Histogram Analysis in Lymphoma Treatment

Study demonstrates that MRI and DWI of patient samples with primary central nervous system lymphoma can be used to predict and monitor disease progression through the use of ADC histogram analysis of Ki-67 expression. oncotarget research Virus cells under the microscope isolated on white background. Scientists have long been aware that lymphoma occurs when multiple genetic changes take place in the white blood cells. This causes the white blood cells to grow out of control and no longer respond to central signaling—which would stop them from overgrowing and aid in natural cell death. However, many other factors driving lymphoma diagnosis have not been fully illuminated. “Primary central nervous system lymphoma (PCNSL) is a rare subgroup of non-Hodgkin lymphoma confined to the central nervous system, with more than 90% of cases classified as Diffuse Large B-cell Lymphoma [1, 2].” “Oncotarget” In a paper published in Oncotarget, researchers from the United States’ Texas, Missouri,
Далее...